iPSC derived NK cells - Pipeline Insight, 2022
This report can be delivered to the clients within 72 hours
DelveInsight’s, “IPSCs derived NK cells – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 30+ pipeline drugs in IPSCs derived NK cells pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
IPSCs derived NK cells: Overview
The discovery of human pluripotent stem cells (PSCs) at the turn of the century opened the door to a new generation of regenerative medicine research. Among PSCs, the donors available for induced pluripotent stem cells (iPSCs) are greatest, providing a potentially universal cell source for all types of cell therapies including cancer immunotherapies using natural killer (NK cells). Unlike primary NK cells, those prepared from iPSCs can be prepared with a homogeneous quality and are easily modified to exert a desired response to tumor cells. iPSC-derived NK (iNK) cells produce inflammatory cytokines and exerted strong cytotoxicity against an array of hematologic and solid tumors. There already exist several protocols to genetically modify and differentiate iPSCs into NK cells, and each has its own advantages with regards to immunotherapies.
'IPSCs derived NK cells - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IPSCs derived NK cells pipeline landscape is provided which includes the disease overview and IPSCs derived NK cells treatment guidelines. The assessment part of the report embraces, in depth IPSCs derived NK cells commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IPSCs derived NK cells collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the IPSCs derived NK cells report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IPSCs derived NK cells Emerging Drugs
Further product details are provided in the report……..
IPSCs derived NK cells: Therapeutic Assessment
This segment of the report provides insights about the different IPSCs derived NK cells drugs segregated based on following parameters that define the scope of the report, such as:
IPSCs derived NK cells: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IPSCs derived NK cells therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IPSCs derived NK cells drugs.
IPSCs derived NK cells Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “IPSCs derived NK cells – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 30+ pipeline drugs in IPSCs derived NK cells pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
IPSCs derived NK cells: Overview
The discovery of human pluripotent stem cells (PSCs) at the turn of the century opened the door to a new generation of regenerative medicine research. Among PSCs, the donors available for induced pluripotent stem cells (iPSCs) are greatest, providing a potentially universal cell source for all types of cell therapies including cancer immunotherapies using natural killer (NK cells). Unlike primary NK cells, those prepared from iPSCs can be prepared with a homogeneous quality and are easily modified to exert a desired response to tumor cells. iPSC-derived NK (iNK) cells produce inflammatory cytokines and exerted strong cytotoxicity against an array of hematologic and solid tumors. There already exist several protocols to genetically modify and differentiate iPSCs into NK cells, and each has its own advantages with regards to immunotherapies.
'IPSCs derived NK cells - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IPSCs derived NK cells pipeline landscape is provided which includes the disease overview and IPSCs derived NK cells treatment guidelines. The assessment part of the report embraces, in depth IPSCs derived NK cells commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IPSCs derived NK cells collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence IPSCs derived NK cells R&D. The therapies under development are focused on novel approaches to treat/improve IPSCs derived NK cells.
This segment of the IPSCs derived NK cells report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IPSCs derived NK cells Emerging Drugs
- EG-HZ: EyeGene
- CRV1O1: Curevo Vaccine
Further product details are provided in the report……..
IPSCs derived NK cells: Therapeutic Assessment
This segment of the report provides insights about the different IPSCs derived NK cells drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in IPSCs derived NK cells
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
IPSCs derived NK cells: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IPSCs derived NK cells therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IPSCs derived NK cells drugs.
IPSCs derived NK cells Report Insights
- IPSCs derived NK cells Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing IPSCs derived NK cells drugs?
- How many IPSCs derived NK cells drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IPSCs derived NK cells?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IPSCs derived NK cells therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for IPSCs derived NK cells and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
IPSCs derived NK cells: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EG-HZ: EyeGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
CRV1O1: Curevo Vaccine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
IPSCs derived NK cells Key Companies
IPSCs derived NK cells Key Products
IPSCs derived NK cells- Unmet Needs
IPSCs derived NK cells- Market Drivers and Barriers
IPSCs derived NK cells- Future Perspectives and Conclusion
IPSCs derived NK cells Analyst Views
IPSCs derived NK cells Key Companies
Appendix
Executive Summary
IPSCs derived NK cells: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EG-HZ: EyeGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
CRV1O1: Curevo Vaccine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
IPSCs derived NK cells Key Companies
IPSCs derived NK cells Key Products
IPSCs derived NK cells- Unmet Needs
IPSCs derived NK cells- Market Drivers and Barriers
IPSCs derived NK cells- Future Perspectives and Conclusion
IPSCs derived NK cells Analyst Views
IPSCs derived NK cells Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for IPSCs derived NK cells
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for IPSCs derived NK cells
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for IPSCs derived NK cells
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for IPSCs derived NK cells
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
